CT-388

CT-388 is a dual GLP-1 and GIP receptor agonist.^[1] In a 24-week trial participants averaged 18.8 percent placebo adjusted weight loss. The drug is developed by Genentech.^[2]^[3]

References[edit]

^ Chakravarthy, Manu; ArgüElles-Tello, Federico A.; Sun, Ana Liza A.; Elliott, Michael; Acosta, Luis; Rankin, Jonathon E.; Hansen, Stig K. (20 June 2023). "75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four Weeks in Overweight and Obese Adults". Diabetes. 72 (Supplement_1). doi:10.2337/db23-75-LB.
^ "Genentech: Press Releases | Wednesday, May 15, 2024". www.gene.com.
^ Constantino, Annika Kim (16 May 2024). "Roche says weight loss drug shows promising results in early trial". CNBC. Retrieved 27 May 2024.

[1] Chakravarthy, Manu; ArgüElles-Tello, Federico A.; Sun, Ana Liza A.; Elliott, Michael; Acosta, Luis; Rankin, Jonathon E.; Hansen, Stig K. (20 June 2023). "75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four Weeks in Overweight and Obese Adults". Diabetes. 72 (Supplement_1). doi:10.2337/db23-75-LB.

[2] "Genentech: Press Releases | Wednesday, May 15, 2024". www.gene.com.

[3] Constantino, Annika Kim (16 May 2024). "Roche says weight loss drug shows promising results in early trial". CNBC. Retrieved 27 May 2024.

[1]

[2]

[3]